This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Scott, A. M. Articles by Old, L. J. Search for Related Content PubMed PubMed Citation Articles by Scott, A. M. Articles by Old, L. J. Related Collections Commentary

A Phase I Dose-Escalation Study of Sibrotuzumab in Patients with Advanced or Metastatic Fibroblast Activation Protein-positive Cancer¹

Ludwig Institute for Cancer Research, Melbourne Tumour Biology Austin, and Repatriation Medical Centre, Melbourne, 3084 Australia [A. M. S., F-T. L., W. H., P. M.]; Mayo Clinic, Rochester, Minnesota 55905 [G. W., A. Ad., L., H. H., D. N. G., J. N. I.]; Memorial Sloan Kettering Cancer Center, New York, New York 10021 [S. W., C. R. D., S. M. L.]; Ludwig Institute for Cancer Research, New York, New York 10158 [S. W., E. W. H., G. R., L. S. C., L. J. O.]; Boehringer Ingelheim Pharma KG, Biberach, 88397 Germany [P. T., P. B., W. J. R.]; and Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut 06877-0368 [L. A., A. Am., D. V.]

Purpose: The purpose of this research was to determine the safety, immunogenicity, pharmacokinetics, biodistribution, and tumor uptake of repeat infusions of a complementarity-determining region grafted humanized antibody (sibrotuzumab) directed against human fibroblast activation protein (FAP).

Experimental Design: A Phase I open-label dose escalation study was conducted in patients with cancers epidemiologically known to be FAP positive. Patients were entered into one of four dosage tiers of 5, 10, 25, or 50 mg/m² sibrotuzumab, administered weekly for 12 weeks, with trace labeling with 8–10 mCi of ¹³¹I in weeks 1, 5, and 9.

Results: A total of 26 patients were entered into the trial (15 males and 11 females; mean age, 59.9 years; age range, 41–81 years). Twenty patients had colorectal carcinoma, and 6 patients had non-small cell lung cancer. A total of 218 infusions of sibrotuzumab were administered during the first 12 weeks of the study, with 24 patients being evaluable. One patient received an additional 96 infusions on continued-use phase for a total of 108 infusions over a 2-year period, and 1 patient received an additional 6 infusions on continued use. There were no objective tumor responses. Only one episode of dose-limiting toxicity was observed. Therefore, a maximum tolerated dose was not reached. Treatment-related adverse events were observed in 6 patients during the infusional monitoring period. Four of the 6 patients, 3 of whom had associated positive serum human antihuman antibody, were removed from the study because of clinical immune responses. Gamma camera images of [¹³¹I]sibrotuzumab demonstrated no normal organ uptake of sibrotuzumab, with tumor uptake evident within 24–48 h after infusion. Analysis of pharmacokinetics demonstrated a similar mean terminal t_1/2 of 1.4–2.6 days at the 5, 10, and 25 mg/m² dose levels, and with a longer mean t_1/2 of 4.9 days at the 50 mg/m² dose level.

Conclusion: Repeat infusions of the humanized anti-FAP antibody sibrotuzumab can be administered safely to patients with advanced FAP-positive cancer.

Commentary

Tumors and Their Microenvironments: Tilling the Soil: Commentary re: A. M. Scott et al., A Phase I Dose-Escalation Study of Sibrotuzumab in Patients with Advanced or Metastatic Fibroblast Activation Protein-positive Cancer. Clin. Cancer Res., 9: 1639–1647, 2003.

Jonathan D. Cheng and Louis M. Weiner
Clin. Cancer Res. 2003 9: 1590-1595. [Full Text] [PDF]

This article has been cited by other articles:

				A. M. LeBeau, W. N. Brennen, S. Aggarwal, and S. R. Denmeade Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin Mol. Cancer Ther., May 1, 2009; 8(5): 1378 - 1386. [Abstract] [Full Text] [PDF]

				B. Zhang Targeting the Stroma by T Cells to Limit Tumor Growth Cancer Res., December 1, 2008; 68(23): 9570 - 9573. [Abstract] [Full Text] [PDF]

				I. Burvenich, S. Schoonooghe, L. Vervoort, C. Dumolyn, E. Coene, L. Vanwalleghem, J. Van Huysse, M. Praet, C. Cuvelier, N. Mertens, et al. Monoclonal antibody 14C5 targets integrin {alpha}v{beta}5 Mol. Cancer Ther., December 1, 2008; 7(12): 3771 - 3779. [Abstract] [Full Text] [PDF]

				E. Ostermann, P. Garin-Chesa, K. H. Heider, M. Kalat, H. Lamche, C. Puri, D. Kerjaschki, W. J. Rettig, and G. R. Adolf Effective Immunoconjugate Therapy in Cancer Models Targeting a Serine Protease of Tumor Fibroblasts Clin. Cancer Res., July 15, 2008; 14(14): 4584 - 4592. [Abstract] [Full Text] [PDF]

				L. R. Henry, H.-O. Lee, J. S. Lee, A. Klein-Szanto, P. Watts, E. A. Ross, W.-T. Chen, and J. D. Cheng Clinical Implications of Fibroblast Activation Protein in Patients with Colon Cancer Clin. Cancer Res., March 15, 2007; 13(6): 1736 - 1741. [Abstract] [Full Text] [PDF]

				A. M. Scott, F.-T. Lee, N. Tebbutt, R. Herbertson, S. S. Gill, Z. Liu, E. Skrinos, C. Murone, T. H. Saunder, B. Chappell, et al. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors PNAS, March 6, 2007; 104(10): 4071 - 4076. [Abstract] [Full Text] [PDF]

				B. Zhang, N. A. Bowerman, J. K. Salama, H. Schmidt, M. T. Spiotto, A. Schietinger, P. Yu, Y.-X. Fu, R. R. Weichselbaum, D. A. Rowley, et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells J. Exp. Med., January 22, 2007; 204(1): 49 - 55. [Abstract] [Full Text] [PDF]

				O. Mendez, B. Martin, R. Sanz, R. Aragues, V. Moreno, B. Oliva, V. Stresing, and A. Sierra Underexpression of transcriptional regulators is common in metastatic breast cancer cells overexpressing Bcl-xL Carcinogenesis, June 1, 2006; 27(6): 1169 - 1179. [Abstract] [Full Text] [PDF]

				E. A. Sausville, A. M. Burger, O. J. Becher, and E. C. Holland Contributions of human tumor xenografts to anticancer drug development. Cancer Res., April 1, 2006; 66(7): 3351 - 3354. [Abstract] [Full Text] [PDF]

				A. M. Scott, F.-T. Lee, R. Jones, W. Hopkins, D. MacGregor, J. S. Cebon, A. Hannah, G. Chong, P. U, A. Papenfuss, et al. A Phase I Trial of Humanized Monoclonal Antibody A33 in Patients with Colorectal Carcinoma: Biodistribution, Pharmacokinetics, and Quantitative Tumor Uptake Clin. Cancer Res., July 1, 2005; 11(13): 4810 - 4817. [Abstract] [Full Text] [PDF]

				G. Chong, F. T. Lee, W. Hopkins, N. Tebbutt, J. S. Cebon, A. J. Mountain, B. Chappell, A. Papenfuss, P. Schleyer, P. U, et al. Phase I Trial of 131I-huA33 in Patients with Advanced Colorectal Carcinoma Clin. Cancer Res., July 1, 2005; 11(13): 4818 - 4826. [Abstract] [Full Text] [PDF]

				Y. S. Jhanwar and C. Divgi Current Status of Therapy of Solid Tumors J. Nucl. Med., January 1, 2005; 46(1_suppl): 141S - 150S. [Abstract] [Full Text] [PDF]

				Y. Huang, S. Wang, and T. Kelly Seprase Promotes Rapid Tumor Growth and Increased Microvessel Density in a Mouse Model of Human Breast Cancer Cancer Res., April 15, 2004; 64(8): 2712 - 2716. [Abstract] [Full Text] [PDF]

				J. D. Cheng and L. M. Weiner Tumors and Their Microenvironments: Tilling the Soil: Commentary re: A. M. Scott et al., A Phase I Dose-Escalation Study of Sibrotuzumab in Patients with Advanced or Metastatic Fibroblast Activation Protein-positive Cancer. Clin. Cancer Res., 9: 1639-1647, 2003. Clin. Cancer Res., May 1, 2003; 9(5): 1590 - 1595. [Full Text] [PDF]